Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of a PROTAC degrader for METTL3-METTL14 complex
Wenhao Du, Yuting Huang, Xiaoai Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 1, pp. 177-183.e17
Closed Access | Times Cited: 24

Showing 24 citing articles:

Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Small molecule inhibitors targeting m6A regulators
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Mechanistic and therapeutic insights into the function of N6-methyladenosine in arthritic diseases
Xinyue Zhou, Yajie Wu, Yingqiu Song, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Closed Access
METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination
Zhuonan Liu, Tianshui Sun, Zhe Zhang, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 2
Open Access
Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4
Danni Rao, Yiting Wang, Xiaolong Yang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 288, pp. 117410-117410
Closed Access
Development of 3-Arylaminothiophenic-2-carboxylic Acid Derivatives as New FTO Inhibitors Showing Potent Antileukemia Activities
Deyan Zhang, Lu Liu, Ming Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117444-117444
Closed Access
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access
Application of Mass Spectrometry for the Advancement of PROTACs
Hao Yin, Baoshuang Zhang, Ruibing Chen
Journal of Pharmaceutical and Biomedical Analysis (2025), pp. 116829-116829
Closed Access
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
G. Li, Wei Chen, Dan Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117560-117560
Closed Access
METTL3 as a master regulator of translation in cancer: mechanisms and implications
Margalida Esteva-Socias, Francesca Aguiló
NAR Cancer (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 4
Challenges to mapping and defining m6A function in viral RNA
Stacy M. Horner, Matthew G. Thompson
RNA (2024) Vol. 30, Iss. 5, pp. 482-490
Open Access | Times Cited: 3
Targeted Degradation of METTL3 Against Acute Myeloid Leukemia and Gastric Cancer.
Kyubin Hwang, Ju‐Hyeon Bae, Yoo-Lim Jhe, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116843-116843
Closed Access | Times Cited: 3
Post‐Translational Modifications of RNA‐Modifying Proteins in Cellular Dynamics and Disease Progression
Yunfan Lin, Pei Lin, Ye Lu, et al.
Advanced Science (2024) Vol. 11, Iss. 44
Open Access | Times Cited: 3
Patent landscape of small molecule inhibitors of METTL3 (2020-present)
Zhixing Wu, Alexis R. Smith, Zhijian Qian, et al.
Expert Opinion on Therapeutic Patents (2024), pp. 1-16
Closed Access | Times Cited: 3
Therapeutic strategies to target the epitranscriptomic machinery
Denise Sighel, Eliana Destefanis, Alessandro Quattrone
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102230-102230
Open Access | Times Cited: 1
The Roles of RNA N6-methyladenosine Modifications in Systemic Lupus Erythematosus
Xin Xia, Rui Qu
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 4, pp. 3223-3234
Closed Access | Times Cited: 1
Targeting METTL3 protein by proteolysis-targeting chimeras: A novel therapeutic approach for acute myeloid leukemia
Rukiye Nar, Zhixing Wu, Yafang Li, et al.
Genes & Diseases (2024), pp. 101452-101452
Open Access | Times Cited: 1
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Shugeng Gao, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 116-144
Closed Access | Times Cited: 1
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations
Qian Zhang, Yanxiang He, Danni Rao, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 1, pp. 753-775
Closed Access | Times Cited: 1
Peptide degrader‐based targeting of METTL3/14 improves immunotherapy response in cutaneous melanoma
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 48
Closed Access | Times Cited: 1
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
Xing Yan, Yuan Yuan Kang, Ze Yan Zhang, et al.
Expert Opinion on Therapeutic Targets (2024)
Closed Access | Times Cited: 1
Targeted Degradation of METTL3 Against Acute Myeloid Leukemia and Gastric Cancer
Kyubin Hwang, Ju‐Hyeon Bae, Yoo-Lim Jhe, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Peptide degrader‐based targeting of METTL3/14 improves immunotherapy response in cutaneous melanoma
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 48
Open Access
METTL3 as a potential therapeutic target in gastric cancer
Zhigang Yu, Yang Yang
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1

Scroll to top